ライフサイエンスコーパス: tolvaptan

1 pnea relief and a possible clinical role for tolvaptan.

2 sferase level were reversible after stopping tolvaptan.

3 on of the vasopressin V2 receptor antagonist tolvaptan.

4 justed life-year gained was even greater for tolvaptan.

5 e associated with the hemodynamic effects of tolvaptan.

6 rescue therapy was also similar at 24 h (21% tolvaptan, 18% placebo; p = 0.57).

7 significantly greater weight reduction with tolvaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.00

8 igned to oral placebo (223 patients) or oral tolvaptan (225) at a dose of 15 mg daily.

9 ble-blind trial, patients were randomized to tolvaptan 30 mg/day or placebo.

10 0 (-1.60 to 0.00) kg in the groups receiving tolvaptan 30, 60, and 90 mg/d, and placebo, respectively

11 Patients were randomized to receive either tolvaptan (30 mg/d) or matching placebo, within 48 hours

12 on of the vasopressin V2-receptor antagonist tolvaptan (30 mg/day) on reducing left ventricular end-d

13 were randomly assigned to placebo (n=63) or tolvaptan [30 mg (n=64), 45 mg (n=64), or 60 mg (n=63)]

14 ients were randomly assigned to receive oral tolvaptan, 30 mg once per day (n = 2072), or placebo (n

15 More patients receiving tolvaptan (684 [76.7%] and 678 [72.1%] for trial A and t

16 er minute or more, in a 2:1 ratio to receive tolvaptan, a V(2)-receptor antagonist, at the highest of

17 tricular ejection fraction < or =40% to oral tolvaptan, a vasopressin antagonist, or placebo and foll

18 In decompensated heart failure (HF), tolvaptan, a vasopressin V(2) receptor antagonist, has b

19 Tolvaptan, a vasopressin V2 receptor blocker, shows prom

20 Tolvaptan administered in addition to standard therapy m

21 Tolvaptan also reduced right atrial pressure (-4.4 +/- 6

22 with euvolemic or hypervolemic hyponatremia, tolvaptan, an oral vasopressin V2-receptor antagonist, w

23 Tolvaptan, an oral, nonpeptide, selective vasopressin V2

24 We investigated whether tolvaptan, an orally active vasopressin V(2)-receptor an

25 A total of 120 patients were randomized to tolvaptan and 120 were randomized to placebo.

26 at 24 h (primary study endpoint) was 16% for tolvaptan and 20% for placebo (p = 0.32).

27 Compounds such as tolvaptan and pasireotide, which indirectly reduce adeny

28 rsening heart failure at 60 days between the tolvaptan and placebo groups (P =.88 for trend).

29 investigating the effects of three doses of tolvaptan and placebo in patients with CHF.

30 The other three drugs namely lansoprazole, tolvaptan and roflumilast, were less potent in suppressi

31 Notably, the V2R-selective inverse agonists tolvaptan and satavaptan completely silenced the constit

32 helin [tezosentan], vasopressin [conivaptan, tolvaptan], and adenosine) and non-cAMP-mediated inotrop

33 Tolvaptan, as compared with placebo, slowed the increase

34 re randomized to double-blind treatment with tolvaptan at a single oral dose (15, 30, or 60 mg) or pl

35 Tolvaptan at all doses significantly reduced pulmonary c

36 Tolvaptan caused increased thirst and dry mouth, but fre

37 The oral vasopressin-2 receptor antagonist tolvaptan causes aquaresis in patients with volume overl

38 espite rapid and persistent weight loss with tolvaptan compared with placebo, in patients with AHF wh

39 At $5760 per month, tolvaptan cost $744 100 per quality-adjusted life-year g

40 Finally, a specific Avpr2 inhibitor, tolvaptan, does not affect bone formation or bone mass,

41 hinese translation BACKGROUND: In the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal

42 tagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) between October 7, 2003, and Februar

43 tagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial investigated the effects of to

44 tagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data,

45 agonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial, which enrolled 4133 patients

46 tagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial, which randomized 4133 patient

47 tagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial.

48 tagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double

49 tagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), an event-driven, randomized, double

50 agonism in Heart Failure: Outcome Study with Tolvaptan [EVEREST]; NCT00071331).

51 111 patients with hyponatremia received oral tolvaptan for a mean follow-up of 701 days, providing 77

52 t improvement from baseline to day 30 in the tolvaptan group according to scores on the Mental Compon

53 p of 9.9 months, 537 patients (25.9%) in the tolvaptan group and 543 (26.3%) in the placebo group die

54 occurred in 38 of 681 patients (5.6%) in the tolvaptan group and in 8 of 685 (1.2%) in the placebo gr

55 re fewer ADPKD-related adverse events in the tolvaptan group but more events related to aquaresis (ex

56 ients with hyponatremia were observed in the tolvaptan group but not in the placebo group.

57 talization for heart failure occurred in 871 tolvaptan group patients (42.0%) and 829 placebo group p

58 sodium concentrations increased more in the tolvaptan group than in the placebo group during the fir

59 , the increase in total kidney volume in the tolvaptan group was 2.8% per year (95% confidence interv

60 idence interval [CI], -2.81 to -1.87) in the tolvaptan group, as compared with -3.61 ml per minute pe

61 (5%) and 21 HF hospitalizations (18%) in the tolvaptan group, compared with 11 deaths (9%) and 34 HF

62 d placebo, respectively (P< or =.008 for all tolvaptan groups vs placebo).

63 L/24 hours at day 1 for 30-, 45-, and 60-mg tolvaptan groups, and placebo, respectively; P<0.001).

64 2 kg was observed in the 30-, 45-, and 60-mg tolvaptan groups, respectively, and a body weight increa

65 tients hospitalized with heart failure, oral tolvaptan in addition to standard therapy including diur

66 rize evidence for decongestion benefits with tolvaptan in AHF and describe the design of the Targetin

67 (Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT0

68 esign of the Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study (TACTICS) an

69 TACTICS-HF (Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conduct

70 xtension of the Study of Ascending Levels of Tolvaptan in Hyponatremia (SALT-1 and SALT-2).

71 Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart F

72 for the symptomatic improvements noted with tolvaptan in patients with decompensated HF.

73 The efficacy and safety of tolvaptan in patients with later-stage ADPKD are unknown

74 (EVEREST) trial investigated the effects of tolvaptan in patients with worsening heart failure and e

75 y 7 or discharge improved significantly with tolvaptan in trial B (P = .02) but did not reach signifi

76 Side effects associated with tolvaptan included increased thirst, dry mouth, and incr

77 ered 2.5% of administered ECVs in the urine; tolvaptan increased recovery five-fold and reduced ECV d

78 Tolvaptan increased urine output by 3 h in a dose-depend

79 Tolvaptan initiated for acute treatment of patients hosp

80 To investigate the effects of tolvaptan initiated in patients hospitalized with heart

81 In conclusion, prolonged administration of tolvaptan maintains an increased serum sodium with an ac

82 Tolvaptan may allow for less intensification of loop diu

83 ast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure

84 (SD) body weight reduction was greater with tolvaptan on day 1 (trial A, 1.71 [1.80] vs 0.99 [1.83]

85 During the week after discontinuation of tolvaptan on day 30, hyponatremia recurred.

86 s of vasopressin V2 receptor antagonism with tolvaptan on the changes in left ventricular (LV) volume

87 there was a significant favorable effect of tolvaptan on the composite of mortality or heart failure

88 In this study, we evaluated the effects of tolvaptan (OPC-41061), a novel, oral, nonpeptide vasopre

89 Treatment with tolvaptan or pasireotide alone markedly reduced cyst pro

90 randomly assigned in a 1:1 ratio to receive tolvaptan or placebo for 12 months.

91 ction </=40% within 48 hours of admission to tolvaptan or placebo for a median follow-up of 9.9 month

92 tion, and were randomized to either 30 mg of tolvaptan or placebo given at 0, 24, and 48 h, with a fi

93 omized to receive 30, 60, or 90 mg/d of oral tolvaptan or placebo in addition to standard therapy, in

94 The composite end point favored tolvaptan over placebo (44 vs. 50 events per 100 follow-

95 t ascites showed directional favorability of tolvaptan over placebo for the primary endpoint compared

96 At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01).

97 Assuming that the benefits of tolvaptan persist in the longer term, the drug may slow

98 Tolvaptan prolonged the median age at ESRD onset by 6.5

99 , the oral vasopressin-2 receptor antagonist tolvaptan, provides benefits related to decongestion and

100 Tolvaptan resulted in a slower decline than placebo in t

101 In patients with advanced HF, tolvaptan resulted in favorable but modest changes in fi

102 Tolvaptan resulted in greater weight loss and net fluid

103 period that included sequential placebo and tolvaptan run-in phases, during which each patient's abi

104 Tolvaptan significantly improved secondary end points of

105 stic Kidney Disease and Its Outcomes) trial, tolvaptan significantly reduced expansion of kidney volu

106 ute), the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume and t

107 Tolvaptan therapy increased the proportion of patients w

108 patients, there was no significant effect of tolvaptan therapy on LV volumes observed during 1 year o

109 Patients received tolvaptan therapy until death, development of ESRD, or l

110 opment of ESRD, or liver complications or no tolvaptan therapy.

111 After 1 year of tolvaptan, there was a small reduction in LV volume (dec

112 It was hypothesized that the addition of tolvaptan to a background diuretic improved dyspnea earl

113 HF, dyspnea, and congestion, the addition of tolvaptan to a standardized furosemide regimen did not i

114 dy was conducted to address the acute use of tolvaptan to improve congestion in AHF.

115 (Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure; NCT00132886

116 nd net fluid loss compared with placebo, but tolvaptan-treated patients were more likely to experienc

117 hoc analysis, 60-day mortality was lower in tolvaptan-treated patients with renal dysfunction or sev

118 Tolvaptan treatment increased AVP levels during follow-u

119 p of patients who had improved outcomes with tolvaptan treatment.

120 agonism in Heart Failure: Outcome Study with Tolvaptan) trial.

121 ry end point showed greater improvement with tolvaptan vs placebo (trial A, mean [SD], 1.06 [0.43] vs

122 h (25% moderately or markedly improved with tolvaptan vs. 28% placebo; p = 0.59) and at 24 h (50% to

123 vs. 28% placebo; p = 0.59) and at 24 h (50% tolvaptan vs. 47% placebo; p = 0.80).

124 acebo groups, respectively; p < 0.05 for all tolvaptan vs. placebo).

125 Tolvaptan was associated with a slower decline in kidney

126 , placebo-controlled trials, the efficacy of tolvaptan was evaluated in patients with euvolemic or hy

127 The dose of tolvaptan was increased to 30 mg daily and then to 60 mg

128 The decrease in body weight with tolvaptan was not associated with changes in heart rate

129 enefit from vasopressin receptor inhibition, tolvaptan was not associated with greater early improvem

130 In patients with CHF, tolvaptan was well tolerated; it reduced body weight and

131 he most common adverse effects attributed to tolvaptan were pollakiuria, thirst, fatigue, dry mouth,

132 To evaluate short-term effects of tolvaptan when added to standard therapy in patients hos

133 n increase in urine volume was observed with tolvaptan when compared with placebo (3.9+/-0.6, 4.2+/-0

134 ed natural history data favored therapy with tolvaptan, with a reduction in the combined end point of

135 during which each patient's ability to take tolvaptan without dose-limiting side effects was assesse